Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TDO2 | P48775 | 1/20 | 0.57 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148373 | 1.00 | IDO1 (0.57) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL148374 | 1.00 | IDO1 (0.57) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL145582 | 0.91 | IDO1 (0.57) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL19465779 | 0.91 | IDO1 (0.57) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL145581 | 0.91 | IDO1 (0.57) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL20199236 | 0.89 | IDO1 (0.51) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL10180880 | 0.88 | IDO1 (0.51) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL17324867 | 0.87 | IDO1 (0.58) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| Epacadostat SCHEMBL29608961 | 0.86 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL146437 | 0.86 | IDO1 (0.69) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4190335-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | Juno Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3525803-B1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS INC (US) | 2022-12-07 | — | — | EP | claimed |
| EP-4190335-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | Juno Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3525803-B1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220323558-A1 | CANCER VACCINES | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |